Rhythm Pharmaceuticals Inc (RYTM) Insider Buys $6,035,000.00 in Stock

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) insider James E. Flynn acquired 355,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 10th. The stock was purchased at an average price of $17.00 per share, for a total transaction of $6,035,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) traded down 14.27% during mid-day trading on Tuesday, reaching $25.72. 504,289 shares of the company traded hands. The stock’s 50 day moving average is $24.57 and its 200 day moving average is $24.57. The stock’s market capitalization is $670.62 million. Rhythm Pharmaceuticals Inc has a 52-week low of $23.99 and a 52-week high of $26.50.

TRADEMARK VIOLATION NOTICE: This story was originally posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.themarketsdaily.com/2017/10/10/rhythm-pharmaceuticals-inc-rytm-insider-buys-6035000-00-in-stock.html.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.

Receive News & Ratings for Rhythm Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply